Register
European Commission Approves Dupilumab for Severe Asthma |
Molecule Updates
eMediNexus Coverage from: 
European Commission Approves Dupilumab for Severe Asthma
eMediNexus,  11 May 2019
remove_red_eye 1474 Views
#Allergy and Immunology #Orthopedics #Pediatrics #Pharmacist

0 Read Comments                

The European Commission (EC) has approved dupilumab (Dupixent) as add-on maintenance therapy for patients 12 years or older with severe asthma with type 2 inflammation characterized by increased blood eosinophil levels and/or increased fractional exhaled nitric oxide, whose condition is poorly controlled with high-dose inhaled corticosteroid plus another medicine.The move follows a recommendation for approval by the European Me
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!